Trial Profile
Multi-center, Phase I Clinical Study to Evaluate the Safety and Tolerability of Multi-antigen Autologous Immune Cell Injection (MASCT-I) in Patients With Advanced Solid Tumor, and to Preliminarily Evaluate the Anti-tumor Efficacy of MASCT-I Alone, in Combination With Chemical Drugs, and in Combination With PD1 Antibody
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 25 Oct 2023
Price :
$35
*
At a glance
- Drugs Camrelizumab (Primary) ; Dendritic cell vaccines (Primary) ; Antineoplastics; Carboplatin; Cisplatin; Doxorubicin; Gemcitabine; Ifosfamide; Platinum complexes
- Indications Bladder cancer; Cholangiocarcinoma; Osteosarcoma; Soft tissue sarcoma; Solid tumours; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Adverse reactions
- Sponsors HengRui YuanZheng Bio-Technology; SYZ Cell Therapy
- 06 Jun 2023 Results (n=39), presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 29 Dec 2022 Planned End Date changed from 1 Jul 2022 to 1 Jul 2023.
- 29 Dec 2022 Planned primary completion date changed from 1 Jul 2022 to 1 Jul 2023.